CCR5

CytoDyn to Host Webcast to Provide Company Update

Retrieved on: 
星期二, 五月 28, 2024
Chairperson, Research, Interim, Biotechnology, Legal Affairs, OTCQB, CCR5

VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executive Officer, will host an investment community webcast on Thursday, May 30, 2024.

Key Points: 
  • VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executive Officer, will host an investment community webcast on Thursday, May 30, 2024.
  • Tanya Urbach, Board Chair, Mitch Cohen, Interim Chief Financial Officer, Tyler Blok, Executive Vice President, Legal Affairs, and Scott Hansen, Head of Research and Basic Science, will join Dr. Lalezari on the call.
  • The Company update will address, among other items, the status of the Company’s prospective clinical trials, recent developments with key research and development partners, and other opportunities the Company will be pursuing to further build out its development portfolio.

Aphios Granted US Patent For siRNA Targeted Therapeutics for Treatment of HIV-1 and Other Diseases

Retrieved on: 
星期三, 五月 15, 2024
AIDS, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, CD4, Rhesus macaque, Human, Disulfiram-like drug, HIV, Corporation, Macaque, Patent, Public, CXCR4, Superfluidity, Infection, Small RNA, Ligand, Cell, CCR5, HIV-1, RNA, Liposome, Therapy, Virus

11,981,174 for CCR5 and CD4 siRNA-targeted therapeutics for treatment of HIV-1 and other diseases.

Key Points: 
  • 11,981,174 for CCR5 and CD4 siRNA-targeted therapeutics for treatment of HIV-1 and other diseases.
  • More than 35 million people have died from AIDS, and 37 million people are living with HIV worldwide.
  • SuperFluids are used to nanoencapsulate siRNA in phospholipid liposomes and lipid nanoparticles (nanosomes) for the improved delivery of siRNA and other biologics to diseased cells.
  • Nanosomal formulation of siRNA and small molecules offers a potential avenue to improving the efficacy of siRNA constructs.

Be Biopharma Announces New Preclinical Data for Novel B Cell Medicine for the Potential Treatment of Hypophosphatasia

Retrieved on: 
星期五, 五月 10, 2024
Biotechnology, Technology, Managed Care, Health, Pharmaceutical, Health Technology, Research, Artificial Intelligence, Genetics, Science, Clinical Trials, Patient, Cas9, Cell, ALPL, Gene expression, Protein, AAV, BCMS, HDR, Disease, HPP, MC3T3, BCM, Gene, CCR5, Injection, Enzyme replacement therapy, Society, CRISPR, DSM-IV codes, ALP, Engineering, Vaccine

Researchers used CRISPR/Cas9 precision gene engineering and artificial intelligence-guided protein design to modify primary human B cells to produce ALP, an enzyme deficient in people living with HPP.

Key Points: 
  • Researchers used CRISPR/Cas9 precision gene engineering and artificial intelligence-guided protein design to modify primary human B cells to produce ALP, an enzyme deficient in people living with HPP.
  • The findings were presented during a poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting on Friday, May 10, at 12:00pm ET.
  • HPP is a rare genetic disease caused by loss of function mutations in the ALPL gene which leads to deficient ALP activity.
  • Robust in vitro phenotypic correction using ALP secreting BCMs (ALP-BCMs) was demonstrated in the MC3T3 osteoblast precursor mineralization model.

Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
星期五, 四月 5, 2024
CDTX, Colorectal cancer, Drug, Adenosine, Patient, SAN, Tavarua, AACR, Therapy, Cancer, Pathology, CCR5, CD73, DFC, San Diego Convention Center, Oleclumab, Escape Room, Vaccine

SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, announced the company will deliver four poster presentations, including one late-breaking poster presentation, at this year’s American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024 at the San Diego Convention Center in San Diego, California. The presentations highlight data on the company’s multispecific CD73/PD-1 drug Fc-conjugate (DFC), its CCR5-targeting DFC, and CBO421, its lead oncology DFC candidate targeting CD73.

Key Points: 
  • The presentations highlight data on the company’s multispecific CD73/PD-1 drug Fc-conjugate (DFC), its CCR5-targeting DFC, and CBO421, its lead oncology DFC candidate targeting CD73.
  • “Our Cloudbreak platform has quickly produced DFC candidates effective in preclinical studies across various cancers with specific disease targets.
  • This week, we are sharing data on our CCR5 DFC program for the first time, which has demonstrated robust efficacy as a monotherapy in mouse models of colorectal cancer.
  • Targeting CCR5 has the potential to improve response rates to immune checkpoint inhibitor therapies, which could have a greater impact for patients unresponsive to these current treatment options.

Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
星期三, 三月 6, 2024
SAN, CDTX, AACR, Therapy, Abstract, Patient, Drug, San Diego Convention Center, DFC, Colorectal cancer, CCR5

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company will be presenting three abstracts and one late-breaking abstract during the American Association for Cancer Research (AACR) Annual Meeting to be held April 5-10, 2024 at the San Diego Convention Center in San Diego, California.

Key Points: 
  • SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company will be presenting three abstracts and one late-breaking abstract during the American Association for Cancer Research (AACR) Annual Meeting to be held April 5-10, 2024 at the San Diego Convention Center in San Diego, California.
  • Presentation details are summarized below:
    Abstract Title: CCR5-001, a novel Drug Fc-Conjugate (DFC) targeting CCR5, demonstrates potent efficacy in a colorectal cancer mouse model
    Presenters: Elizabeth Abelovski and Nicholas Dedeic, Ph.D.

CytoDyn Announces FDA Has Lifted Clinical Hold

Retrieved on: 
星期四, 二月 29, 2024
Clinical trial, FDA, OTCQB, Publication, Biotechnology, HIV, CCR5, Pharmaceutical industry

VANCOUVER, Washington, Feb. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the FDA has lifted the clinical hold on leronlimab. The Company is now free to proceed with its proposed HIV clinical trial exploring leronlimab and its effects on chronic inflammation.

Key Points: 
  • Webcast to Provide Company Update on March 5, 2024
    VANCOUVER, Washington, Feb. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the FDA has lifted the clinical hold on leronlimab.
  • The Company is now free to proceed with its proposed HIV clinical trial exploring leronlimab and its effects on chronic inflammation.
  • CytoDyn's CEO, Dr. Jacob Lalezari, stated, "We are excited that the clinical hold on leronlimab has been lifted by the FDA.
  • The update will include a discussion about the Company's clinical trial goals and expectations, upcoming publications, and overall development strategy moving forward.

City of Hope Research Featuring the Successful Treatment of the Oldest Patient to Achieve Remission for Leukemia and HIV Published in The New England Journal of Medicine (NEJM)

Retrieved on: 
星期三, 二月 14, 2024
Oncology, AIDS, Health, Infectious Diseases, Hospitals, Research, Science, Infection, Bone marrow, Cancer, Division, Immune system, Multimedia, Syndrome, Graft-versus-host disease, Acute leukemia, Blood, CCR5, Haematopoietic system, Transplant, Government, BMT, National Cancer Institute, Laboratory, B cell, Gene therapy, Medicare, Patient, Mutation, HIV, Dentistry

View the full release here: https://www.businesswire.com/news/home/20240214747351/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240214747351/en/
    "City of Hope Patient" Paul Edmonds with City of Hope doctors, Jana K. Dickter, M.D., and Monzr Al Malki, M.D.
  • Edmonds is also the person who had HIV the longest — for over 31 years — among these five patients.
  • Known as the “City of Hope patient” among these five patients, Edmonds received a transplant at City of Hope on Feb. 6, 2019, and is now considered to be cured of leukemia.
  • City of Hope has exceptional transplant outcomes year after year, according to the Center for International Blood & Marrow Transplant Research.

CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma

Retrieved on: 
星期四, 二月 1, 2024
Partnership, Glioblastoma, Inflammation, Research, OTCQB, Montefiore Medical Center, HIV, Leronlimab, Patient, Splenic infarction, Stroke, FDA, Biotechnology, CCR5, Pharmaceutical industry

The Company believes this submission will lead to the removal of the clinical hold currently in effect.

Key Points: 
  • The Company believes this submission will lead to the removal of the clinical hold currently in effect.
  • CytoDyn’s CEO, Dr. Jacob Lalezari stated, “Our HIV protocol has been revised and resubmitted following FDA input, and will study leronlimab in HIV patients who have increased inflammation and immune activation, which causes heart attacks, strokes, and other vascular events.
  • Glioblastoma is a common and often untreatable form of primary brain cancer.
  • CytoDyn is fortunate to be able to evaluate the potential effects of leronlimab in a pre-clinical model of this all too often deadly cancer.”

CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO

Retrieved on: 
星期一, 一月 29, 2024
CFO, Biotechnology, Partnership, OTCQB, CCR5, HIV, FDA

Following his appointment as interim CEO in November 2023, a consensus developed by the board that Dr. Lalezari was the outstanding candidate and is the right leader for CytoDyn at this time.

Key Points: 
  • Following his appointment as interim CEO in November 2023, a consensus developed by the board that Dr. Lalezari was the outstanding candidate and is the right leader for CytoDyn at this time.
  • Mr. Cohen will be working with Mr. Migliarese to facilitate a smooth transition over the next several weeks.
  • As to the appointment of Mitch Cohen as interim CFO, Chair Tanya Urbach noted, “We look forward to working with Mr. Cohen.
  • CytoDyn is confident in Mr. Cohen’s ability to lead our financial operations after his successfully serving as CFO and interim executive for numerous companies.

Non-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032 | DelveInsight

Retrieved on: 
星期三, 一月 17, 2024
Obesity, Merck & Co., MRI, LAS, Weight loss, Fatty liver disease, Type 2 diabetes, Magnetic resonance imaging, Insulin resistance, NASH, FFAR4, Liver, Liver disease, Diabetes, Alcoholic liver disease, Therapy, Hypertension, PPAR, Eli Lilly and Company, Gilead Sciences, Chronic pain, Disease, Inflammation, FASN, AstraZeneca, Novo Nordisk, FXR, Prevalence, CCR5, FGF, Physical examination, Weakness, Bronchial thermoplasty, Cilofexor, Metabolic syndrome, Mitsubishi Tanabe Pharma, Development, NAFLD, Risk, Fibrosis, Fatigue, Dyslipidemia, USD, Non-alcoholic fatty liver disease, Merck, Pharmaceutical industry

LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.

Key Points: 
  • LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.
  • According to DelveInsight's analysis, the market size for NASH reached USD 200 million in 2022 in Japan and is expected to grow with a significant CAGR by 2032.
  • DelveInsight's analysis reveals that the overall diagnosed prevalent population of NASH in Japan was reported as 2.5 million in 2022.
  • Among the forecasted emerging therapies, MGL-3196 (Resmetirom) is expected to capture the highest market in Japan by 2032.